Clearside Biomedical Announces First Successful Human Dosing in a Safety and Tolerability Study in Patients With Retinal Disease

Published: Nov 06, 2012

ATLANTA--(BUSINESS WIRE)--Clearside Biomedical, Inc., a privately held company specializing in the research and development of ophthalmic pharmaceuticals, today announced the successful dosing of patients in a safety and tolerability clinical study using its proprietary ocular microinjection platform to deliver therapeutics to treat retinal disease.

Back to news